We have collected the questions overseas manufacturers ask most often when coordinating submissions for China, with answers drawn from hands-on experience. Every product is different — confirm your specific pathway with us before committing to a plan.
Start with classification determination. Confirm the product's risk class (I, II or III) against the Medical Device Classification Catalogue — the class decides whether you file or register, who reviews, and the timeline expectation. Where classification is unclear, a classification determination can be requested. Do this before any dossier work; a wrong class is among the most expensive rework errors in practice.
Yes. Overseas registrants and record-holders must designate a Chinese enterprise legal person as their agent to handle registration and filing, adverse event monitoring and recalls. The agent is a regulatory role, distinct from a distributor: distributors sell, the agent answers to the regulator. The agent's details are part of the dossier, and changing agents later requires a change filing.
Filing is comparatively simple: prepare the filing dossier (risk analysis, product technical requirements, test reports, labelling and IFU drafts, evidence documents, etc.) and submit through the filing platform to the NMPA for foreign products. Complete and compliant dossiers receive a filing certificate. Note that filing does not mean exemption from oversight — post-market obligations apply all the same.
Core materials typically include: the application form, evidence documents (including evidence of market authorization abroad), the list of essential principles of safety and performance, product technical requirements, test reports, clinical evaluation materials and QMS documentation. Imported Class III products may also face registration quality system verification, including on-site inspection arrangements at overseas manufacturing sites. The exact list follows the rules applicable at acceptance — plan for "right the first time".
Yes, under conditions. China accepts foreign clinical trial data subject to the ethical and scientific requirements of the relevant guidelines; the exemption catalogue and predicate-based evaluation routes are also available. Most products with prior market experience do not need to run Chinese clinical trials from scratch — the earlier you plan the pathway, the better your position.
A medical device registration certificate is valid for 5 years. To renew, apply to the original authority six months before expiry; a missed deadline means starting a fresh first registration. In practice, start the renewal assessment 9–12 months ahead to leave room for deficiencies and verification.
Not necessarily. Changes fall into two groups: substantive (licensed) changes — product name, models, composition, intended use — and record-level (registered) changes such as the holder's or agent's name. Each follows its own route. When anything changes, first classify the change, then decide whether a filing is required — avoiding both "should-have-filed" and "filed-when-unnecessary".
Devices marketed in China must carry Chinese labels and Chinese instructions for use, including the smallest sales unit. Content must match the registered version, so labels and IFUs are controlled documents — evaluate any change for potential registration impact before adopting it.
